Embecta Corp. (EMBC) stock
EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3080% below fair value
$6.09−0.06 (-0.98%)
Close on Nov 18, 2026Market cap $345.06MP/E 4.1Yield 9.85%
Embecta gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Embecta's gross profit for the twelve months ending Jun 30, 2026 was $601.30M, down 13.1% year over year. For fiscal 2025 it was $676.80M, down 7.9% from the year before. The highest annual figure on record is $800.40M in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $676.80M | -7.9% |
| FY2024 | Sep 30, 2024 | $735.20M | -2.0% |
| FY2023 | Sep 30, 2023 | $749.90M | -3.2% |
| FY2022 | Sep 30, 2022 | $774.90M | -3.2% |
| FY2021 | Sep 30, 2021 | $800.40M | +5.0% |
| FY2020 | Sep 30, 2020 | $762.60M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $153.30M | -22.2% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $127.80M | -22.1% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $161.70M | +2.9% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $158.50M | -8.8% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $197.10M | +3.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $164.10M | -11.5% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $157.10M | -15.5% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $173.80M | -4.4% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $190.10M | +0.3% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $185.40M | -2.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $185.90M | -1.5% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $181.80M | +2.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $189.50M | -6.6% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $189.80M | -0.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $188.80M | -7.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $176.90M | -15.8% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $202.90M | +0.1% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $191.20M | -2.6% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $203.90M | +6.6% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $210.20M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $202.60M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $196.30M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $191.30M | – |
See a number that looks wrong?